Last reviewed · How we verify
Pneumococcal Pneumonia vaccine
Pneumococcal Pneumonia vaccine is a Biologic drug developed by Boston Medical Center. It is currently in Phase 2 development. Also known as: PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ), PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA)..
At a glance
| Generic name | Pneumococcal Pneumonia vaccine |
|---|---|
| Also known as | PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ), PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA). |
| Sponsor | Boston Medical Center |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age (PHASE3)
- Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
- Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (PHASE2)
- A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal Pneumonia vaccine CI brief — competitive landscape report
- Pneumococcal Pneumonia vaccine updates RSS · CI watch RSS
- Boston Medical Center portfolio CI
Frequently asked questions about Pneumococcal Pneumonia vaccine
What is Pneumococcal Pneumonia vaccine?
Pneumococcal Pneumonia vaccine is a Biologic drug developed by Boston Medical Center.
Who makes Pneumococcal Pneumonia vaccine?
Pneumococcal Pneumonia vaccine is developed by Boston Medical Center (see full Boston Medical Center pipeline at /company/boston-medical-center).
Is Pneumococcal Pneumonia vaccine also known as anything else?
Pneumococcal Pneumonia vaccine is also known as PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ), PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA)..
What development phase is Pneumococcal Pneumonia vaccine in?
Pneumococcal Pneumonia vaccine is in Phase 2.
Related
- Manufacturer: Boston Medical Center — full pipeline
- Also known as: PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ), PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA).
- Compare: Pneumococcal Pneumonia vaccine vs similar drugs
- Pricing: Pneumococcal Pneumonia vaccine cost, discount & access